Australia markets open in 4 hours 18 minutes

Immutep Limited (IMM.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.2750-0.0100 (-3.51%)
At close: 4:10PM AEDT

Immutep Limited

95 Pitt Street
Level 12
Sydney, NSW 2000
Australia
61 2 8315 7003
http://www.immutep.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Marc VoigtCEO, CFO, Chief Bus. Officer & Exec. Director456.42kN/A1973
Ms. Deanne MillerCOO, Gen. Counsel & Company Sec.280.12kN/A1977
Dr. Frederic TriebelChief Scientific Officer & Chief Medical Officer279.12kN/A1955
Mr. Thomas Robert John BloomfieldCompany Sec.N/AN/AN/A
Mr. Christian MuellerDirector of Clinical Devel. & Regulatory AffairsN/AN/AN/A
Mr. Shengfei FangFin. Director & Assistant Company Sec.N/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ‘eftilagimod alpha' or ‘efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Corporate governance

Immutep Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.